Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors
This is a Phase 1 dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in patients with advanced or metastatic solid tumors. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 for Phase 2 studies
Neoplasms|Solid Tumors|Metastases
DRUG: BMS-754807
Safety - Toxicities will be evaluated according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 3, Continuous assessment throughout the duration of the trial
Pharmacokinetics, assessed during the first 4 weeks of the study|Pharmacodynamics, assessed during the first 4 weeks of the study|Metabolic measures, assessed during the first 4 weeks of the study|ECG, assessed during the first 4 weeks of the study|Efficacy Measures, assessed every 8 weeks
This is a Phase 1 dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in patients with advanced or metastatic solid tumors. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 for Phase 2 studies